Monster Beats, Billion-Dollar Bets & November Fireworks
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is published by Stock Region for informational, educational, and entertainment purposes only. Nothing contained herein constitutes financial, investment, legal, or tax advice, nor is it a recommendation to buy, sell, or hold any security. Trading equities—especially small-cap, micro-cap, and volatile catalyst-driven stocks—carries a high degree of risk and can result in the loss of your entire investment. The opinions expressed below are strictly those of the author and do not represent guaranteed outcomes. Always conduct your own due diligence and consult a licensed financial professional before making any investment decisions.
What a stretch in the markets, Stock Region family. If you have been sleeping on the morning wires over the last two weeks, you have missed absolute fireworks. We have seen everything from a casual billion-dollar cash injection to earnings beats that look like typos, alongside tech partnerships with some of the biggest whales on the planet.
This market is rewarding companies that actually execute and punishing the ones that lag behind. Grab your coffee, pull up your charts, and let’s dive into the plays that have the Stock Region desk buzzing right now.
“She perceives that her merchandise is profitable: her lamp goeth not out by night.” — Proverbs 31:18
The Heavy Hitters & Billion-Dollar Headlines
$CKX (CKX Lands): Let’s start with the elephant in the room. Brad Jacobs is leading a $1 billion cash equity investment into CKX Lands. Whenever Brad Jacobs steps into a ticker with a ten-figure war chest, you stop what you are doing and pay attention. The man has a legendary track record of building massive conglomerates out of overlooked shells. In my opinion, this completely transforms $CKX from a sleepy land play into one of the most fascinating long-term institutional transformation stories on the board.
$LUNR (Intuitive Machines): Space is no longer a science fair project; it is a booming business. Intuitive Machines dropped Q3 numbers and swept the board—record revenue, profitability, positive cash flow, and a record backlog. You rarely see space stocks hit positive cash flow this cleanly. For my money, $LUNR is proving it is the undisputed commercial leader in lunar infrastructure.
$PXLW (Pixelworks): Partnering with Meta to bring TrueCut Motion cinematic content to the newly launched Meta VR glasses is a massive validation of Pixelworks’ tech. Small-cap hardware/software plays live and die by tier-1 adoption, and landing inside Meta’s ecosystem is about as big as it gets. If VR/AR hardware adoption accelerates this holiday season, $PXLW has a serious tailwind.
$XMAX (XMax): Landing an AI infrastructure services agreement expected to generate over $100 million in revenue over the next five years is a monster catalyst. The market is starting to separate companies that just slap “AI” in their press releases from companies actually signing nine-figure infrastructure deals. Keep a close eye on how they scale delivery here.
Earnings Season Thrillers (And One Chill)
$VTSI (VirTra): Talk about blowing the doors off the hinges! VirTra reported Q3 EPS of $0.19 against an analyst consensus of $(0.03)—a 1,050% beat—while sales hit $7.623 million, crushing estimates by over 73%. When a company flips from an expected loss to nearly twenty cents of profit per share in a single quarter, shorts get trapped fast. Hands down my favorite earnings report of the batch.
$SEGG (SEGG Media): Reporting more than 1,500% year-over-year revenue growth in Q2, driven by Veloce. Triple- and quadruple-digit growth numbers always draw momentum traders like moths to a flame. The key here will be whether they can sustain margins while scaling at breakneck speed.
$FTCI (FTC Solar): Solar has been a tough neighborhood lately, which makes FTC Solar’s Q3 stand out even more. Revenue jumped 25% quarter-over-quarter, they guided for a massive 46% sequential revenue jump in Q4, and they locked in new project wins with heavyweights like Tata Power Solar and Brookfield-backed Evren. Targeting Adjusted EBITDA profitability in 2027 with a loaded pipeline makes this a premier turnaround candidate in clean energy.
$GXAI (Gaxos): Quietly posted a massive 464.9% year-over-year revenue increase (and 14.5% sequential growth) for Q3. Huge top-line expansion that momentum scanners love.
$WKSP (Worksport): Record Q3 net sales of $7.23 million (up 44.2% YoY) while narrowing their net loss by 28%. I love seeing top-line records paired with tightening losses—it shows management isn’t just buying revenue at the expense of the balance sheet.
$MRLN (Merlin): What a swing! Q3 EPS came in at $0.37 compared to a brutal loss of $(5.24) last year, with revenue nearly doubling from $1.9M to $3.5M YoY. That is a textbook operational turnaround.
$CIIT: Full-year revenue climbed to $14.24 million (up from $9.28 million last year), powered by their newly launched global mineral trading business, which contributed $4.41 million (31% of total revenue) right out of the gate. Smart diversification paying off immediately.
$DGXX (Digi Power X) & $MITQ (Moving iMage Technologies): Digi Power X saw Q3 revenue jump a clean 50% YoY. Meanwhile, $MITQ grew Q1 sales to $6.094M (up from $5.582M YoY), though EPS dipped from $0.05 to $0.02. Solid top-line resilience for both, though $MITQ needs to watch its bottom-line margin compression.
$HRTX (Heron Therapeutics): The lone wet blanket in the earnings pile. They met EPS loss estimates at $(0.03), which is an improvement over last year’s $(0.04) loss, but revenue missed by 6% at $35.25 million (down 7.75% YoY). In a market with so many companies beating numbers, missing on the top line makes $HRTX a “show-me” story for now.
$PEPG (PepGen): Dropped Q3 financial results and corporate updates—worth keeping on the secondary monitor to see how the street digests their cash runway into 2027.
Biotech, MedTech & FDA Catalysts
$BEAT (HeartBeam): Huge validation at TCT 2026. Their patient-recorded 3D ECG matched the accuracy of a standard hospital 12-lead ECG in a heart attack pilot study. If patients can get hospital-grade heart attack detection from a credit-card-sized device at home, that is a genuine paradigm shift in cardiology. I am very bullish on the real-world utility here.
$DTIL (Precision BioSciences): Dropped late-breaking PBGENE-HBV data at AASLD The Liver Meeting demonstrating cccDNA elimination and the potential to drive an actual viral cure for Hepatitis B. “Cure” is the heaviest word in biotech—if subsequent clinical trials hold this line, $DTIL could command serious big-pharma partnership interest.
$KPTI (Karyopharm Therapeutics): Double catalyst week. First, they halted for a planned merger with Ayrmid Ltd. to fortify the company, and then followed up two days later announcing Selinexor data presentations for myelofibrosis and multiple myeloma at the upcoming ASH meeting. M&A plus a major hematology showcase keeps $KPTI firmly in play.
$CNSY (Cerenome): Secured a national in-network agreement with Aetna for CNSide. Regulatory approval is only half the battle in diagnostics; insurance reimbursement is where the actual money is made. Getting Aetna on board opens the commercial floodgates.
$VJET (Catheter Precision): Bagged a new FDA 510(k) clearance for its VIVO System, expanding the addressable patient population. More patients cleared equals a bigger commercial TAM.
$CJMB (Callan JMB): Announced the arrival of Rapid Dose Therapeutics’ QuickStrip, projecting $15 million in revenue over the next 18 months. For a small-cap, an $833k/month average revenue run-rate addition is a massive needle-mover.
$TOVX (Theriva Biologics): Sold off its SYN-004 (ribaxamase) and antibiotic-degrading enzyme portfolio to Biossil Labs. Shedding non-core assets to streamline focus and bring in cash is usually a smart move in a tight biotech funding environment.
$ENVB (Enveric Biosciences): Preclinical qEEG study data for EB-003 supported CNS penetration and brain activity differentiated from classic DMT. Next-gen neuroplastogens without the hallucinogenic trip are the holy grail of mental health biotech right now.
$MBOT (Microbot Medical), $SINT (SINTX Technologies), $BDMD (Baird Medical) & $AMIX (Autonomix): A great cluster of med-device progress. $MBOT locked down a Canadian patent for an adaptor connecting surgical tools to robotic devices; $SINT is pushing its SiN/PEEK 3D printing platform toward personalized orthopedic implants; $BDMD expanded into South Korea via a distribution deal with ALLIS MED; and $AMIX showcased its renal denervation vision at TCT 2026. Out of these four,$BDMD’s immediate commercial distribution expansion into South Korea feels like the quickest path to near-term revenue.
Defense, Robotics & Tech Deals
$INLF (Inlif): Entered a $30 million framework agreement with Heng Sheng Group to expand into industrial robotics. Thirty million dollars is serious weight in the industrial automation space—watch for when framework orders convert into binding purchase orders.
$XTND (XTEND AI Robotics) & $DFNS (T3 Defense): Defense and autonomous drones remain red-hot. $XTND scored an $8.3 million defense order for systems in the Asia-Pacific region, while $DFNS delivered a UAV Command & Control Center to BlueBird Aero Systems. Geopolitical tensions aren’t cooling down anytime soon, and autonomous defense contractors are seeing steady, tangible order flow.
$NEXR (Nexera Technologies): Completed the sale of KeepZone AI to a global aerospace and defense company for up to $6.5 million. Clean monetization of an AI asset.
$BKYI (BIO-key): Another two-punch combo! First, they broke into the gaming and hospitality sector with a contract from a major U.S. casino resort. Second, they reported Q3 software license fees grew 39%—their third straight quarter of double-digit growth, fueled by momentum in Europe and the Middle East. Consistent software license growth is high-margin beauty.
$PHUN (Phunware): Their interactive maps and patient wayfinding are now live in the Toolbox on the Epic Showroom. Integrating directly into Epic’s healthcare ecosystem gives Phunware visibility in front of major hospital systems across the country.
$CYAB (Cyabra) & $SMX: Cyabra locked in a six-figure deal with a major media company to detect coordinated online manipulation (bots and deepfakes are a growing headache for media giants), while $SMX expanded its tech portfolio with an AI-powered scientific intelligence platform.
Energy, SPACs & Balance Sheet Wins
$SAFX (XCF Global) & $ONFO (Onfolio): If there is one thing retail traders hate, it is dilution and reverse splits. XCF Global ($SAFX) actually withdrew its reverse stock split proposal and reaffirmed its growth strategy—you have to respect a management team that listens to shareholders rather than crushing the float. Similarly, Onfolio ($ONFO) announced its stockholders’ equity is back above the Nasdaq minimum with zero convertible notes outstanding. Toxic debt is the silent killer of small caps, so a clean balance sheet on $ONFO is a massive green flag.
$ELAB (NorthStrive Acquisition Corp I) vs. $RDAC (Rising Dragon Acquisition Corp.): A tale of two SPACs. $ELAB announced a business combination with Nuclea Energy—and with nuclear power hungry to power AI data centers, nuclear mergers are prime momentum fuel. On the flip side, $RDAC and HZJL Cayman mutually terminated their merger agreement. In my book, $ELAB goes right onto the front burner, while$RDAC goes to the back of the shelf until they find a new target.
$RBNE (Robin Energy) & $VIVK (Vivakor): Robin Energy declared a $0.10 per share special dividend—nothing beats cold, hard cash returned to shareholders. Meanwhile, Vivakor brought on energy infrastructure veteran Bernard Brown to advance their airport hydrogen project.
$LABT, $POLA, $POM & $OGEN: The compliance and cleanup crew. Lakewood-Amedex ($LABT) completed its Series C convertible preferred stock redemption (cleaning up the cap table), Polar Power ($POLA) and Pomdoctor ($POM) officially regained Nasdaq compliance, and Oragenics ($OGEN) secured NYSE American approval for its compliance plan through February 2028. Removing delisting risk takes a massive weight off these charts.
Stay sharp out there, manage your risk, never chase extended green candles without a plan, and let’s make the rest of November count!
Disclaimer: The information provided in this newsletter by Stock Region is for general informational and educational purposes only and is not intended to be, nor should it be construed as, financial, investment, or trading advice. Stock Region is not a registered investment advisor or broker-dealer. All opinions, analyses, and commentary reflect the personal views of the author as of the date of publication and are subject to change without notice. Past performance is not indicative of future results. Small-cap and micro-cap securities are subject to extreme volatility, illiquidity, and dilution risk. Readers are solely responsible for their own investment decisions and should independently verify all corporate press releases, SEC filings, and financial data before trading.

